Author Archives: matthew.sherwood

Melissa Burroughs Pena meets with leaders in Cardiovascular Global Health


This week I attended the final meeting of the NHLBI/ United Health Centers of Excellence Steering Committee. Duke Cardiology was well represented at the meeting, which involves many global leaders in cardiovascular research. Eric Velazquez and Jerry Bloomfield attended the meeting in conjunction with collaborators from the Center of Excellence in Eldoret, Kenya. It was a unique opportunity to look to the future of cardiovascular global health research as we near the conclusion of the Center of Excellence program. This program funded 11 cardiovascular research centers across the globe including the CRONICAS research center where I work in Peru. This network has not only facilitated career development, but also has provided a mechanism for interdisciplinary collaboration. For example, my current project on household air pollution exposure and left ventricular function brings together the infrastructure of the CRONICAS Center’s population cohort study in Peru and the expertise of the Duke Cardiac Diagnostic Unit and the Duke Clinical Research Institute in conducting echocardiography-based research. These types of partnerships broaden the reach of Duke cardiovascular research worldwide.

Mohamed Abdel-Wahab discusses the controversial short-term results of the CHOICE trial

Matthew Sherwood, Duke Cardiology Fellow, discusses the controversial results of the CHOICE trial with Dr. Mohamed Abdel-Wahab, Director of Cardiac Catheterization Lab in Bad Segeburg, Germany and the PI of the trial. He touches on the limitations of these short term outcomes, and what will come with the presentation of long term follow up next year.

Dr. Bob Harrington discusses STABILITY and trial design at ACC 14

Matthew Sherwood, Duke Cardiology fellow, discusses the results of the STABILITY trial with Bob Harrington, Chair of Medicine at Stanford and former Director of the DCRI. They also discussed how SOLID trial results in the future will inform the results found in STABILITY and the strategy of industry sponsors in developing a platform of trials in stable CAD and ACS patients. This has been the standard in antithrombotics, but is interesting to see in anti-lipid drugs.